BlackRock Inc. lifted its holdings in shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 76.5% during the second quarter, HoldingsChannel.com reports. The firm owned 1,144,920 shares of the company’s stock after purchasing an additional 496,306 shares during the quarter. BlackRock Inc.’s holdings in Dova Pharmaceuticals were worth $34,257,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently made changes to their positions in DOVA. JPMorgan Chase & Co. increased its holdings in Dova Pharmaceuticals by 148.6% in the 1st quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock worth $145,000 after acquiring an additional 3,195 shares during the last quarter. Commonwealth Equity Services LLC purchased a new stake in Dova Pharmaceuticals in the 2nd quarter worth about $215,000. Jane Street Group LLC purchased a new stake in Dova Pharmaceuticals in the 1st quarter worth about $220,000. Rhumbline Advisers purchased a new stake in Dova Pharmaceuticals in the 2nd quarter worth about $337,000. Finally, Schwab Charles Investment Management Inc. increased its holdings in Dova Pharmaceuticals by 36.4% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 13,500 shares of the company’s stock worth $367,000 after acquiring an additional 3,600 shares during the last quarter. 36.57% of the stock is owned by institutional investors.

DOVA stock opened at $20.63 on Friday. The company has a quick ratio of 13.14, a current ratio of 13.19 and a debt-to-equity ratio of 0.17. The stock has a market cap of $586.89 million, a price-to-earnings ratio of -14.74 and a beta of 0.30. Dova Pharmaceuticals Inc has a twelve month low of $19.25 and a twelve month high of $37.00.

Dova Pharmaceuticals (NASDAQ:DOVA) last posted its earnings results on Thursday, August 9th. The company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.07). The business had revenue of $4.58 million during the quarter. Sell-side analysts expect that Dova Pharmaceuticals Inc will post -2.76 EPS for the current fiscal year.

Several brokerages recently weighed in on DOVA. BidaskClub raised Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 13th. ValuEngine raised Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 29th. Finally, Zacks Investment Research raised Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a report on Wednesday, October 10th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $33.20.

In related news, CEO Alex Sapir bought 21,700 shares of Dova Pharmaceuticals stock in a transaction on Tuesday, August 14th. The stock was acquired at an average price of $22.83 per share, with a total value of $495,411.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 55.50% of the stock is owned by insiders.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Recommended Story: Conference Calls

Want to see what other hedge funds are holding DOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dova Pharmaceuticals Inc (NASDAQ:DOVA).

Institutional Ownership by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.